• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Point of Care Molecular Diagnostics Market

    ID: MRFR/MED/49956-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    UK Point-of-care Molecular Diagnostics Market Research Report By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Application (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), and By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Point of Care Molecular Diagnostics Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    UK Point of Care Molecular Diagnostics Market Summary

    The United Kingdom Point-of-care Molecular Diagnostics market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    UK Point-of-care Molecular Diagnostics Key Trends and Highlights

    • The market is valued at 312.5 USD Million in 2024 and is expected to reach 975 USD Million by 2035.
    • The compound annual growth rate (CAGR) for the market is estimated at 10.9% from 2025 to 2035.
    • This growth trajectory indicates a robust expansion in the adoption of molecular diagnostics technologies across the UK.
    • Growing adoption of point-of-care testing due to the increasing demand for rapid diagnostic solutions is a major market driver.

    Market Size & Forecast

    2024 Market Size 312.5 (USD Million)
    2035 Market Size 975 (USD Million)
    CAGR (2025-2035) 10.9%

    Major Players

    Rapid Medical Diagnostics, bioMérieux, Hologic, GenomOncology, Roche Diagnostics, Becton Dickinson, MDx Health, Abbott Laboratories, Cepheid, A. Menarini Diagnostics, Siemens Healthineers, Molecular Testing Labs, Qiagen, Thermo Fisher Scientific, Princeton BioMeditech Corporation

    UK Point of Care Molecular Diagnostics Market Trends

    The point-of-care molecular diagnostics market in the UK is expanding significantly due to a number of important market factors. Point-of-care testing is becoming more popular as a result of the growing need for quick and precise diagnostic data, which enables doctors to decide on treatments in a timely manner.

    Molecular diagnostics are now used in basic healthcare settings in the UK as a result of efforts to increase healthcare access and efficiency. By emphasising patient-centric services, NHS efforts that promote innovation and the use of technology in healthcare also contribute to this trend.

    The growing incidence of genetic abnormalities and infectious diseases, which necessitates the need for speedier diagnostic solutions, are opportunities to be investigated in this industry.

    Point-of-care molecular diagnostics' capabilities complement the UK government's emphasis on early diagnosis and preventative care through its investments in healthcare technology and models like the NHS Long Term Plan.

    The need for remote diagnostics has also grown as a result of the COVID-19 epidemic and the acceleration of telemedicine, which further presents chances for market participants to develop. The development of portable diagnostic tools that may be utilised in a variety of locations, such as clinics and patients' homes, is one of the recent trends in the UK point-of-care molecular diagnostics market.

    The goal of the growing alliances between digital companies and healthcare providers is to expand the capabilities and reach of products.

    Furthermore, a wider adoption of molecular testing throughout the healthcare system is being facilitated by the growing knowledge and acceptability of the procedure among patients and medical professionals. These patterns show that the UK is moving towards more accessible and decentralised diagnostic solutions in an effort to enhance patient outcomes and expedite the delivery of healthcare.

    UK Point-of-care

    UK Point of Care Molecular Diagnostics Market Drivers

    Market Segment Insights

    UK

    UK Point-of-care Molecular Diagnostics Market Segment Insights

    Point-of-care

    Point-of-care Molecular Diagnostics Market Product Type Insights

    The UK Point-of-care Molecular Diagnostics Market is characterized by a diverse array of Product Types, essential for delivering efficient and rapid diagnostic solutions across healthcare settings. PCR Tests are a vital component, recognized for their ability to amplify DNA and provide precise results, making them crucial for the detection of infectious diseases and genetic conditions.

    Nucleic Acid Amplification Tests have gained significant traction due to their capacity for enhancing the detection of pathogens by identifying specific nucleic acid sequences, and these tests are widely used in monitoring and diagnosing various infections.

    The Microarray technology segment is notable for its ability to analyze multiple genes simultaneously, enabling healthcare providers to make informed decisions based on comprehensive genetic data. This is particularly beneficial in personalized medicine, where treatment can be tailored to the individual based on their genetic profile.

    Point-of-care

    Point-of-care Molecular Diagnostics Market Application Insights

    The Application segment of the UK Point-of-care Molecular Diagnostics Market is critical to the overall landscape, addressing a range of healthcare needs through advanced diagnostic technologies. This segment includes disciplines such as Infectious Diseases, Genetic Testing, Cancer Diagnosis, and Metabolic Disorders, each playing a significant role in modern healthcare.

    Infectious Diseases diagnostics, driven by a growing prevalence of conditions like COVID-19, emphasizes the need for rapid and accurate results directly at the Point-of-care. Genetic Testing has gained attention due to its importance in personalized medicine, enabling tailored therapies and early detection of hereditary conditions, thus improving patient outcomes.

    Cancer Diagnosis remains vital, as early identification significantly enhances treatment effectiveness and survival rates, strengthening the call for innovative point-of-care solutions. Metabolic Disorders testing is also crucial, particularly for conditions like diabetes, where timely detection and management can prevent severe health complications.

    Point-of-care

    Point-of-care Molecular Diagnostics Market End-use Insights

    The UK Point-of-care Molecular Diagnostics Market is diversely structured across various End-use categories that cater to specific healthcare needs. Hospitals are leading the demand for molecular diagnostics due to the need for rapid and accurate testing in critical care settings.

    Diagnostic Laboratories play a vital role by providing a comprehensive analysis of diseases, thus ensuring better patient management and outcomes. Home Care Settings have gained traction, enabling patients to monitor health conditions from the comfort of their homes, significantly enhancing convenience and compliance.

    Outpatient Clinics contribute to the market by facilitating onsite testing, which streamlines the diagnostic process and reduces the need for multiple visits. The growing emphasis on early detection and personalized medicine is driving innovations across all these areas, with a clear focus on improving patient care.

    Point-of-care

    Point-of-care Molecular Diagnostics Market Technology Insights

    The UK Point-of-care Molecular Diagnostics Market showcases a diverse Technology segment that encompasses various methodologies, each contributing significantly to effective diagnostics. Isothermal Amplification methods are increasingly favored for their efficiency in delivering rapid test results without the need for sophisticated equipment, making them valuable in emergency and remote settings.

    Polymerase Chain Reaction (PCR) remains a cornerstone technique due to its high specificity and sensitivity, widely used across infectious disease diagnostics and genetic testing. Sanger Sequencing serves as a crucial technology for its reliable accuracy in sequencing DNA, forming the basis for numerous applications, including personalized medicine.

    CRISPR Technology represents a revolutionary advancement, offering the potential for precise gene editing and diagnostics, thus unlocking new avenues for treating genetic disorders.

    Get more detailed insights about UK Point of Care Molecular Diagnostics Market Research Report- Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The UK Point-of-care Molecular Diagnostics Market has been experiencing significant growth due to advancements in technology, increasing demand for rapid testing, and a heightened focus on personalized medicine. Key players in this market are continually innovating to offer improved diagnostic solutions that become essential for efficient clinical decision-making.

    The competitive landscape is characterized by strategic collaborations, mergers, and a surge in research and development activities aimed at enhancing the accuracy and speed of molecular diagnostics.

    With an increasing number of healthcare providers adopting new point-of-care testing methods, the market has become increasingly dynamic, making it essential to analyze the strengths and positioning of the leading companies within this sector.

    Rapid Medical Diagnostics has carved out a notable presence in the UK Point-of-care Molecular Diagnostics Market by focusing on creating innovative and user-friendly diagnostic kits that cater to various healthcare settings. The company has utilized its expertise to streamline testing processes, thereby reducing turnaround times for results which is crucial in emergency situations.

    Its strengths lie in rapid test kits that provide high sensitivity and specificity, making them reliable for healthcare professionals. By leveraging strong customer relationships and an understanding of local market needs, Rapid Medical Diagnostics has established a robust distribution network that enables fast access to its products across the UK.

    This customer focus combined with a commitment to quality underlines its competitive advantage in the growing market.

    bioMérieux, a prominent player in the UK Point-of-care Molecular Diagnostics Market, offers a wide range of diagnostic solutions tailored to meet the urgent needs of healthcare providers. The company possesses strong market presence through its innovative platforms that encompass molecular testing capabilities such as PCR and next-generation sequencing.

    Its key products are instrumental in the rapid identification of infectious diseases, which has become increasingly critical in today’s healthcare landscape. bioMérieux is recognized for its cutting-edge technology and an extensive portfolio that emphasizes accuracy and speed in diagnostics.

    Additionally, bioMérieux has engaged in strategic mergers and acquisitions to bolster its capabilities in molecular diagnostics, further enhancing its market position. Their commitment to research and development alongside strong partnerships within the healthcare ecosystem enables them to stay at the forefront of the industry, addressing the evolving needs of the UK healthcare market effectively.

    Key Companies in the UK Point of Care Molecular Diagnostics Market market include

    Industry Developments

    The UK Point-of-care Molecular Diagnostics Market has seen substantial developments recently, particularly following the impact of the COVID-19 pandemic. Companies such as Roche Diagnostics and Abbott Laboratories have expanded their product offerings to include rapid testing solutions, enhancing the speed and accuracy of diagnoses in various healthcare settings.

    In September 2023, Hologic announced an increase in their market presence by introducing new diagnostic platforms aimed at women's health, which are expected to cater to the growing demand for point-of-care testing.

    Recent advances in technology by Cepheid and bioMérieux have also improved the detection of infectious diseases, creating a competitive landscape focused on innovation and efficiency. Additionally, in July 2023, a merger was reported between Molecular Testing Labs and A. Menarini Diagnostics, forming a stronger entity aligned to address the rising needs in molecular diagnostics.

    This competitive environment is influencing the market's growth trajectory, as the UK government actively invests in healthcare technology, creating an ecosystem that fosters advancements in point-of-care diagnostics. Overall, the emphasis on rapid and accurate testing continues to propel investments and innovations within the UK Point-of-care Molecular Diagnostics Market.

    UK Point-of-care

    Market Segmentation

    Point-of-care Molecular Diagnostics Market End-useOutlook

    • Hospitals
    • Diagnostic Laboratories
    • Home Care Settings
    • Outpatient Clinics

    Point-of-care Molecular Diagnostics Market Technology Outlook

    • Isothermal Amplification
    • Polymerase Chain Reaction
    • Sanger Sequencing
    • CRISPR Technology

    Point-of-care Molecular Diagnostics Market Application Outlook

    • Infectious Diseases
    • Genetic Testing
    • Cancer Diagnosis
    • Metabolic Disorders

    Point-of-care Molecular Diagnostics Market Product Type Outlook

    • PCR Tests
    • Nucleic Acid Amplification Tests
    • Microarray
    • Next-Generation Sequencing
    • Other Genetic Tests

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 259.65(USD Million)
    MARKET SIZE 2024 312.5(USD Million)
    MARKET SIZE 2035 975.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 10.898% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Rapid Medical Diagnostics, bioMérieux, Hologic, GenomOncology, Roche Diagnostics, Becton Dickinson, MDx Health, Abbott Laboratories, Cepheid, A. Menarini Diagnostics, Siemens Healthineers, Molecular Testing Labs, Qiagen, Thermo Fisher Scientific, Princeton BioMeditech Corporation
    SEGMENTS COVERED Product Type, Application, End Use, Technology
    KEY MARKET OPPORTUNITIES Rising demand for rapid testing, Technological advancements in devices, Increased prevalence of infectious diseases, Growing focus on patient-centered care, Expanding applications in personalized medicine
    KEY MARKET DYNAMICS growing demand for rapid testing, increasing prevalence of infectious diseases, advancements in molecular technology, cost-effective diagnostic solutions, expansion of home healthcare services
    COUNTRIES COVERED UK

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the UK Point of Care Molecular Diagnostics Market in 2024?

    The market is expected to be valued at 312.5 million USD in 2024.

    What is the projected market size for the UK Point of Care Molecular Diagnostics Market by 2035?

    By 2035, the market is expected to reach a valuation of 975.0 million USD.

    What is the compound annual growth rate (CAGR) for the UK Point of Care Molecular Diagnostics Market from 2025 to 2035?

    The market is anticipated to grow at a CAGR of 10.898 percent during the forecast period.

    Which product segment is expected to have the largest market share in 2024?

    PCR Tests are projected to dominate with a market value of 120.0 million USD in 2024.

    How much is the market for Nucleic Acid Amplification Tests expected to grow by 2035?

    The market for Nucleic Acid Amplification Tests is expected to reach 240.0 million USD by 2035.

    Who are the key players in the UK Point of Care Molecular Diagnostics Market?

    Major players include Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers among others.

    What market value is expected for Microarray products by 2035?

    The market for Microarray products is projected to be valued at 160.0 million USD by 2035.

    What segment is projected to show the least market value in 2024?

    Other Genetic Tests are expected to have the least market value at 30.0 million USD in 2024.

    What are the anticipated growth opportunities in the UK Point of Care Molecular Diagnostics Market?

    Emerging technologies and the increasing demand for rapid diagnostics present significant growth opportunities.

    What is the expected market value for Next-Generation Sequencing by 2035?

    Next-Generation Sequencing is projected to grow to 120.0 million USD by 2035.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. UK Point of Care Molecular Diagnostics Market, BY Product Type (USD Million)
    45. PCR Tests
    46. Nucleic Acid Amplification Tests
    47. Microarray
    48. Next-Generation Sequencing
    49. Other Genetic Tests
    50. UK Point of Care Molecular Diagnostics Market, BY Application (USD Million)
    51. Infectious Diseases
    52. Genetic Testing
    53. Cancer Diagnosis
    54. Metabolic Disorders
    55. UK Point of Care Molecular Diagnostics Market, BY End Use (USD Million)
    56. Hospitals
    57. Diagnostic Laboratories
    58. Home Care Settings
    59. Outpatient Clinics
    60. UK Point of Care Molecular Diagnostics Market, BY Technology (USD Million)
    61. Isothermal Amplification
    62. Polymerase Chain Reaction
    63. Sanger Sequencing
    64. CRISPR Technology
    65. Competitive Landscape
    66. Overview
    67. Competitive Analysis
    68. Market share Analysis
    69. Major Growth Strategy in the Point of Care Molecular Diagnostics Market
    70. Competitive Benchmarking
    71. Leading Players in Terms of Number of Developments in the Point of Care Molecular Diagnostics Market
    72. Key developments and growth strategies
    73. New Product Launch/Service Deployment
    74. Merger & Acquisitions
    75. Joint Ventures
    76. Major Players Financial Matrix
    77. Sales and Operating Income
    78. Major Players R&D Expenditure. 2023
    79. Company Profiles
    80. Rapid Medical Diagnostics
    81. Financial Overview
    82. Products Offered
    83. Key Developments
    84. SWOT Analysis
    85. Key Strategies
    86. bioMérieux
    87. Financial Overview
    88. Products Offered
    89. Key Developments
    90. SWOT Analysis
    91. Key Strategies
    92. Hologic
    93. Financial Overview
    94. Products Offered
    95. Key Developments
    96. SWOT Analysis
    97. Key Strategies
    98. GenomOncology
    99. Financial Overview
    100. Products Offered
    101. Key Developments
    102. SWOT Analysis
    103. Key Strategies
    104. Roche Diagnostics
    105. Financial Overview
    106. Products Offered
    107. Key Developments
    108. SWOT Analysis
    109. Key Strategies
    110. Becton Dickinson
    111. Financial Overview
    112. Products Offered
    113. Key Developments
    114. SWOT Analysis
    115. Key Strategies
    116. MDx Health
    117. Financial Overview
    118. Products Offered
    119. Key Developments
    120. SWOT Analysis
    121. Key Strategies
    122. Abbott Laboratories
    123. Financial Overview
    124. Products Offered
    125. Key Developments
    126. SWOT Analysis
    127. Key Strategies
    128. Cepheid
    129. Financial Overview
    130. Products Offered
    131. Key Developments
    132. SWOT Analysis
    133. Key Strategies
    134. A. Menarini Diagnostics
    135. Financial Overview
    136. Products Offered
    137. Key Developments
    138. SWOT Analysis
    139. Key Strategies
    140. Siemens Healthineers
    141. Financial Overview
    142. Products Offered
    143. Key Developments
    144. SWOT Analysis
    145. Key Strategies
    146. Molecular Testing Labs
    147. Financial Overview
    148. Products Offered
    149. Key Developments
    150. SWOT Analysis
    151. Key Strategies
    152. Qiagen
    153. Financial Overview
    154. Products Offered
    155. Key Developments
    156. SWOT Analysis
    157. Key Strategies
    158. Thermo Fisher Scientific
    159. Financial Overview
    160. Products Offered
    161. Key Developments
    162. SWOT Analysis
    163. Key Strategies
    164. Princeton BioMeditech Corporation
    165. Financial Overview
    166. Products Offered
    167. Key Developments
    168. SWOT Analysis
    169. Key Strategies
    170. References
    171. Related Reports
    172. UK Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD Billions)
    173. UK Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    174. UK Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    175. UK Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    176. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    177. ACQUISITION/PARTNERSHIP
    178. MARKET SYNOPSIS
    179. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY PRODUCT TYPE
    180. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY APPLICATION
    181. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY END USE
    182. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY
    183. KEY BUYING CRITERIA OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    184. RESEARCH PROCESS OF MRFR
    185. DRO ANALYSIS OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    186. DRIVERS IMPACT ANALYSIS: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    187. RESTRAINTS IMPACT ANALYSIS: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    188. SUPPLY / VALUE CHAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    189. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2025 (% SHARE)
    190. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019 TO 2035 (USD Billions)
    191. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 (% SHARE)
    192. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    193. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2025 (% SHARE)
    194. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    195. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    196. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    197. BENCHMARKING OF MAJOR COMPETITORS

    UK Point of Care Molecular Diagnostics Market Segmentation

    • Point of Care Molecular Diagnostics Market By Product Type (USD Million, 2019-2035)

      • PCR Tests
      • Nucleic Acid Amplification Tests
      • Microarray
      • Next-Generation Sequencing
      • Other Genetic Tests

     

    • Point of Care Molecular Diagnostics Market By Application (USD Million, 2019-2035)

      • Infectious Diseases
      • Genetic Testing
      • Cancer Diagnosis
      • Metabolic Disorders

     

    • Point of Care Molecular Diagnostics Market By End Use (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Home Care Settings
      • Outpatient Clinics

     

    • Point of Care Molecular Diagnostics Market By Technology (USD Million, 2019-2035)

      • Isothermal Amplification
      • Polymerase Chain Reaction
      • Sanger Sequencing
      • CRISPR Technology

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027